Scarborough Advisors’s Gilead Sciences GILD Stock Holding History

Scarborough Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-253	Closed	-$35.2K	–	357
2026 Q1	$35.2K	Buy	+253	New	+$35.4K	﹤0.01%	270

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Scarborough Advisors's GILD Position: Q2 2026 in Review

Scarborough Advisors sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 253 shares — an estimated $35.2K sold.

Scarborough Advisors first reported a position in GILD in Q1 2026 and held it in 1 quarter. The position peaked at $35.2K in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Scarborough Advisors reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
Scarborough Advisors sold 253 Gilead Sciences shares in Q2 2026, an estimated $35.2K.
Scarborough Advisors first reported a position in Gilead Sciences in Q1 2026 and held it in 1 quarter.
Scarborough Advisors's Gilead Sciences position peaked at $35.2K in Q1 2026.
2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Scarborough Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.